Bioanalytical Systems (BASI) Competitors

bioAffinity Technologies (NASDAQ:BIAF) and Bioanalytical Systems (NASDAQ:BASI) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, dividends, risk, analyst recommendations, earnings, valuation, profitability, institutional ownership and community ranking.

Does the MarketBeat Community favor BIAF or BASI?

Bioanalytical Systems received 128 more outperform votes than bioAffinity Technologies when rated by MarketBeat users.

Company	Underperform	Outperform
bioAffinity Technologies	N/A	N/A
Bioanalytical Systems	Outperform Votes 128 41.69%	Underperform Votes 179 58.31%

Do institutionals and insiders believe in BIAF or BASI?

1.6% of bioAffinity Technologies shares are owned by institutional investors. Comparatively, 10.6% of Bioanalytical Systems shares are owned by institutional investors. 44.3% of bioAffinity Technologies shares are owned by insiders. Comparatively, 11.5% of Bioanalytical Systems shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock is poised for long-term growth.

Do analysts rate BIAF or BASI?

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
bioAffinity Technologies	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A
Bioanalytical Systems	0 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	N/A

Is BIAF or BASI more profitable?

Bioanalytical Systems has a net margin of -7.75% compared to Bioanalytical Systems' net margin of -313.34%. bioAffinity Technologies' return on equity of -42.74% beat Bioanalytical Systems' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
bioAffinity Technologies	-313.34%	-107.20%	-84.10%
Bioanalytical Systems	-7.75%	-42.74%	-6.38%

Which has better earnings & valuation, BIAF or BASI?

Bioanalytical Systems has higher revenue and earnings than bioAffinity Technologies. Bioanalytical Systems is trading at a lower price-to-earnings ratio than bioAffinity Technologies, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
bioAffinity Technologies	$2.53M	11.15	-$7.94M	-$0.90	-2.72
Bioanalytical Systems	$60.47M	0.72	-$4.68M	-$0.35	-11.20

Which has more risk and volatility, BIAF or BASI?

bioAffinity Technologies has a beta of 3.14, suggesting that its share price is 214% more volatile than the S&P 500. Comparatively, Bioanalytical Systems has a beta of 1.92, suggesting that its share price is 92% more volatile than the S&P 500.

Does the media favor BIAF or BASI?

In the previous week, bioAffinity Technologies had 10 more articles in the media than Bioanalytical Systems. MarketBeat recorded 11 mentions for bioAffinity Technologies and 1 mentions for Bioanalytical Systems. bioAffinity Technologies' average media sentiment score of 0.00 beat Bioanalytical Systems' score of -0.14 indicating that Bioanalytical Systems is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
bioAffinity Technologies	0 Very Positive mention(s)	0 Positive mention(s)	9 Neutral mention(s)	1 Negative mention(s)	0 Very Negative mention(s)	Neutral
Bioanalytical Systems	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral

Summary

Bioanalytical Systems beats bioAffinity Technologies on 9 of the 14 factors compared between the two stocks.